Certain Argon Plasma Coagulation System Probes, Their Components, and Other Argon Plasma Coagulation System Components for Use Therewith Commission Determination Not To Review an Initial Determination Terminating the Investigation as to Certain Respondents and Granting Leave To Amend the Complaint and Notice of Investigation, 12016-12017 [2020-04109]
Download as PDF
jbell on DSKJLSW7X2PROD with NOTICES
12016
Federal Register / Vol. 85, No. 40 / Friday, February 28, 2020 / Notices
of Kowloon, Hong Kong (‘‘IFree’’) based
on a partial withdrawal of the
complaint.
FOR FURTHER INFORMATION CONTACT:
Robert Needham, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–5468. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on September 23, 2019, based on a
complaint filed by Brother Industries,
Ltd., of Nagoya, Japan; Brother
International Corporation (U.S.A.) of
Bridgewater, New Jersey; and Brother
Industries (U.S.A.), Inc., of Bartlett,
Tennessee (together, ‘‘Brother’’). 84 FR
49762–63. The complaint, as
supplemented, alleges violations of
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, in the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain toner cartridges, components
thereof, and systems containing same by
reason of infringement of certain claims
of U.S. Patent Nos. 9,568,856; 9,575,460;
9,632,456; 9,785,093; and 9,846,387. Id.
The Commission’s notice of
investigation named 32 respondents,
including EPrinter and IFree. Id. at
49763. The Office of Unfair Import
Investigations (‘‘OUII’’) is participating
in this investigation. Id.
On January 10, 2020, Brother filed a
motion seeking leave to amend the
complaint and notice of investigation to
correct the name for one respondent and
to correct the address for seven
respondents. Brother also sought to
terminate the investigation with respect
to EPrinter and IFree based on a partial
withdrawal of the complaint due to the
inability to serve those parties with the
complaint and notice of investigation.
On January 22, 2020, OUII filed a
response in support of the motion.
VerDate Sep<11>2014
17:27 Feb 27, 2020
Jkt 250001
On January 28, 2020, the ALJ issued
the subject ID, and ordered that the
complaint and notice of investigation be
amended as requested. The subject ID
additionally terminated the
investigation with respect to EPrinter
and IFree based on the withdrawal of
the complaint with respect to those
entities. No petitions for review of the
ID were received.
The Commission has determined not
to review the subject ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: February 25, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–04108 Filed 2–27–20; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1182]
Certain Argon Plasma Coagulation
System Probes, Their Components,
and Other Argon Plasma Coagulation
System Components for Use Therewith
Commission Determination Not To
Review an Initial Determination
Terminating the Investigation as to
Certain Respondents and Granting
Leave To Amend the Complaint and
Notice of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission (‘‘Commission’’) has
determined not to review an initial
determination (‘‘ID’’) of the presiding
administrative law judge (‘‘ALJ’’)
terminating this investigation as to
certain respondents and granting leave
to amend the complaint and notice of
investigation to add a respondent.
FOR FURTHER INFORMATION CONTACT: Ron
Traud, Office of the General Counsel,
U.S. International Trade Commission,
500 E Street SW, Washington, DC
20436, telephone 202–205–3427. Copies
of non-confidential documents filed in
connection with this investigation are or
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (‘‘EDIS’’) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal, telephone 202–205–1810.
On
November 8, 2019, the Commission
instituted this investigation based on a
complaint filed by Erbe Elektromedizin
GmbH of the Republic of Germany and
Erbe USA, Inc. of Marietta, Georgia. 84
FR 60451. The complaint alleges
violations of section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337
based upon the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain argon plasma
coagulation system probes, their
components, and other argon plasma
coagulation system components for use
therewith by reason of infringement of
certain claims of U.S. Patent Nos.
D577,671; 7,311,707; 7,717,911;
9,510,889; and 9,603,653. Id. The
Commission’s notice of investigation
named the following as respondents: (1)
Olympus Corporation of Tokyo, Japan;
(2) Olympus Corporation of the
Americas of Center Valley,
Pennsylvania; (3) Olympus America of
Center Valley, Pennsylvania; (4)
Olympus Surgical Technologies Europe
of Hamburg, Republic of Germany; (5)
Olympus Winter & lbe GmbH of
Hamburg, Republic of Germany; (6)
Olympus KeyMed Group Limited of
Essex, United Kingdom; (7) KeyMed
(Medical & Industrial Equipment) Ltd.
of Essex, United Kingdom; (8) Olympus
Bolton of Bolton, United Kingdom; (9)
Olympus Surgical Technologies Europe
| Cardiff of Cardiff, United Kingdom. Id.
at 60451–52. The Office of Unfair
Import Investigations was also named as
a party to this investigation. Id. at
60452.
On January 27, 2020, the private
parties filed a joint, unopposed motion
seeking to terminate this investigation
in part based on withdrawal of the
complaint as to named respondents
Olympus KeyMed Group Limited,
KeyMed (Medical & Industrial
Equipment) Ltd., Olympus Bolton, and
Olympus Surgical Technologies Europe
| Cardiff. The motion also sought to
amend the complaint and notice of
investigation to add Gyrus Medical Ltd.
as a named respondent.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\28FEN1.SGM
28FEN1
Federal Register / Vol. 85, No. 40 / Friday, February 28, 2020 / Notices
On January 29, 2020, the ALJ issued
Order No. 10, the subject ID, granting
the motion. The ID finds that the motion
complies with the Commission’s Rules
and that no extraordinary circumstances
warrant denying the motion. No
petitions for review of the subject ID
were filed.
The Commission has determined not
to review the subject ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
upon request and payment of the
copying fee set by Department of Justice
regulations.
Public comment is invited within 60
days of the date of this notice. Such
comments, including the name of the
submitter, and responses thereto, will be
posted on the Antitrust Division’s
website, filed with the Court, and, under
certain circumstances, published in the
Federal Register Comments should be
directed to Katrina Rouse, Chief,
Defense, Industrials, and Aerospace
Section, Antitrust Division, Department
of Justice, 450 Fifth Street NW, Suite
8700, Washington, DC 20530
(telephone: 202–598–2459).
By order of the Commission.
Issued: February 25, 2020.
Lisa Barton,
Secretary to the Commission.
Amy Fitzpatrick,
Counsel to the Senior Director of
Investigations and Litigation.
UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA
[FR Doc. 2020–04109 Filed 2–27–20; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Antitrust Division
jbell on DSKJLSW7X2PROD with NOTICES
United States v. Olympus Growth Fund
VI, L.P., et al.; Proposed Final
Judgment and Competitive Impact
Statement
Notice is hereby given pursuant to the
Antitrust Procedures and Penalties Act,
15 U.S.C. 16(b)–(h), that a proposed
Final Judgment, Stipulation, and
Competitive Impact Statement have
been filed with the United States
District Court for the District of
Columbia in United States of America v.
Olympus Growth Fund VI, L.P., et al.,
Civil Action No. 1:20–cv–00464. On
February 19, 2020, the United States
filed a Complaint alleging that the
proposed acquisition of the Plastics
Division of DS Smith plc by Olympus
Growth Fund VI, L.P., through its
portfolio company Liqui-Box, Inc.,
would violate Section 7 of the Clayton
Act, 15 U.S.C. 18. The proposed Final
Judgment, filed at the same time as the
Complaint, requires Defendants to
divest all of DS Smith’s Bag-in-Box
(BiB) product lines that overlap with
BiB product lines offered by Liqui-Box
in the United States, including those for
dairy, post-mix, smoothie, and wine.
Copies of the Complaint, proposed
Final Judgment, and Competitive Impact
Statement are available for inspection
on the Antitrust Division’s website at
https://www.justice.gov/atr and at the
Office of the Clerk of the United States
District Court for the District of
Columbia. Copies of these materials may
be obtained from the Antitrust Division
VerDate Sep<11>2014
17:27 Feb 27, 2020
Jkt 250001
UNITED STATES OF AMERICA, U.S.
Department of Justice, Antitrust Division, 450
5th Street NW, Suite 8700, Washington, DC
20530, Plaintiff, v. OLYMPUS GROWTH
FUND VI, L.P., One Station Place, Stamford,
CT 06902, LIQUI-BOX, INC., 901 E. Byrd
Street, Richmond, VA 23219, and DS SMITH
PLC, 350 Euston Road, London, NW1 3AX,
Defendants.
Civil Action No.: 1:20–cv–00464
Judge: Hon. Christopher Cooper
Complaint
The United States of America
(‘‘United States’’), acting under the
direction of the Attorney General of the
United States, brings this civil antitrust
action against Defendants Olympus
Growth Fund VI, L.P. (‘‘Olympus’’),
Liqui-Box, Inc. (‘‘Liqui-Box’’), and DS
Smith plc (‘‘DS Smith’’) to enjoin
Olympus’s proposed acquisition of DS
Smith’s Plastics Division (‘‘DS Smith
Plastics’’), through Liqui-Box, a
portfolio company of Olympus. The
United States complains and alleges as
follows:
I. Nature of the Action
1. Pursuant to a Stock Purchase
Agreement dated March 5, 2019, LiquiBox proposes to acquire DS Smith
Plastics for approximately $500 million,
making the combined company one of
the largest bag-in-box (‘‘BiB’’) suppliers
in the United States.
2. BiBs are engineered plastic bags
used to store and dispense liquids such
as milk, post-mix (e.g., soda syrups and
other beverage concentrates), smoothies,
and wine. BiBs are made up of a single
or multi-layer plastic film bag and an
attached fitment, which is a plastic
component used to facilitate the transfer
of the liquids into and out of the bags.
After a BiB is manufactured, it is
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
12017
shipped empty to the customer, who
fills the BiB with liquid and then sells
the filled BiB. Customers, such as
dairies, soft-drink manufacturers, and
other food producers, rely on BiBs to
preserve and safely transport their
liquids to restaurants, convenience
stores, other food service operators, and
retail outlets.
3. In the United States, Liqui-Box and
DS Smith are two of only three
significant suppliers of BiBs for nearly
all end uses, including dairy, post-mix,
and smoothies. Liqui-Box and DS Smith
also are two of only four significant
suppliers of BiBs for wine in the United
States. The proposed acquisition will
eliminate competition between LiquiBox and DS Smith to supply these BiBs
to customers and is likely to lead to
increased prices, lower quality and
service, and less innovation.
4. As a result, the proposed
acquisition likely would substantially
lessen competition for the development,
manufacture, and sale of dairy, postmix, smoothie, and wine BiBs in the
United States in violation of Section 7
of the Clayton Act, 15 U.S.C. 18, and
should be enjoined.
II. The Parties and the Transaction
5. Olympus, a fund managed by
private equity firm Olympus Partners, is
a Delaware limited partnership with
headquarters in Stamford, Connecticut.
In 2018, Olympus Partners had
approximately $8.5 billion total capital
under management between its different
funds, with Olympus comprising
approximately $2.3 billion of that total.
6. Liqui-Box, a company owned by
Olympus, is a Delaware corporation
with headquarters in Richmond,
Virginia. Liqui-Box is a global
manufacturer of packaging and
packaging equipment, including BiBs,
with four U.S. manufacturing facilities,
as well as additional facilities across the
world. In 2018, Liqui-Box had total sales
of $177 million, including
approximately $123 million in the
United States.
7. DS Smith is a United Kingdom
public limited company with
headquarters in London, England. DS
Smith is a global manufacturer of
packaging, packaging equipment, and
recycled paper. DS Smith operates DS
Smith Plastics, a division that
manufactures flexible packaging and
dispensing solutions, rigid packaging,
injection-molded products, and foam
products. Among DS Smith Plastics’
flexible packaging products are BiBs,
which are primarily sold under the
Rapak brand name in the United States.
DS Smith Plastics has its U.S.
headquarters in Romeoville, Illinois,
E:\FR\FM\28FEN1.SGM
28FEN1
Agencies
[Federal Register Volume 85, Number 40 (Friday, February 28, 2020)]
[Notices]
[Pages 12016-12017]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04109]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1182]
Certain Argon Plasma Coagulation System Probes, Their Components,
and Other Argon Plasma Coagulation System Components for Use Therewith
Commission Determination Not To Review an Initial Determination
Terminating the Investigation as to Certain Respondents and Granting
Leave To Amend the Complaint and Notice of Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission (``Commission'') has determined not to review an initial
determination (``ID'') of the presiding administrative law judge
(``ALJ'') terminating this investigation as to certain respondents and
granting leave to amend the complaint and notice of investigation to
add a respondent.
FOR FURTHER INFORMATION CONTACT: Ron Traud, Office of the General
Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone 202-205-3427. Copies of non-
confidential documents filed in connection with this investigation are
or will be available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Washington, DC 20436,
telephone 202-205-2000. General information concerning the Commission
may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed
on the Commission's electronic docket (``EDIS'') at https://edis.usitc.gov. Hearing-impaired persons are advised that information
on this matter can be obtained by contacting the Commission's TDD
terminal, telephone 202-205-1810.
SUPPLEMENTARY INFORMATION: On November 8, 2019, the Commission
instituted this investigation based on a complaint filed by Erbe
Elektromedizin GmbH of the Republic of Germany and Erbe USA, Inc. of
Marietta, Georgia. 84 FR 60451. The complaint alleges violations of
section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 based
upon the importation into the United States, the sale for importation,
or the sale within the United States after importation of certain argon
plasma coagulation system probes, their components, and other argon
plasma coagulation system components for use therewith by reason of
infringement of certain claims of U.S. Patent Nos. D577,671; 7,311,707;
7,717,911; 9,510,889; and 9,603,653. Id. The Commission's notice of
investigation named the following as respondents: (1) Olympus
Corporation of Tokyo, Japan; (2) Olympus Corporation of the Americas of
Center Valley, Pennsylvania; (3) Olympus America of Center Valley,
Pennsylvania; (4) Olympus Surgical Technologies Europe of Hamburg,
Republic of Germany; (5) Olympus Winter & lbe GmbH of Hamburg, Republic
of Germany; (6) Olympus KeyMed Group Limited of Essex, United Kingdom;
(7) KeyMed (Medical & Industrial Equipment) Ltd. of Essex, United
Kingdom; (8) Olympus Bolton of Bolton, United Kingdom; (9) Olympus
Surgical Technologies Europe [bond] Cardiff of Cardiff, United Kingdom.
Id. at 60451-52. The Office of Unfair Import Investigations was also
named as a party to this investigation. Id. at 60452.
On January 27, 2020, the private parties filed a joint, unopposed
motion seeking to terminate this investigation in part based on
withdrawal of the complaint as to named respondents Olympus KeyMed
Group Limited, KeyMed (Medical & Industrial Equipment) Ltd., Olympus
Bolton, and Olympus Surgical Technologies Europe [bond] Cardiff. The
motion also sought to amend the complaint and notice of investigation
to add Gyrus Medical Ltd. as a named respondent.
[[Page 12017]]
On January 29, 2020, the ALJ issued Order No. 10, the subject ID,
granting the motion. The ID finds that the motion complies with the
Commission's Rules and that no extraordinary circumstances warrant
denying the motion. No petitions for review of the subject ID were
filed.
The Commission has determined not to review the subject ID.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: February 25, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020-04109 Filed 2-27-20; 8:45 am]
BILLING CODE 7020-02-P